Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Ulefnersen (ION363 ) in Amyotrophic lateral sclerosis. The expected timing is based on the latest available company guidance and may change.
Phase 3 trial was initiated in first half of 2021. Data in 2026 01/11/26:- FUSION Ph3 ALS trial results expected in 2026 as part of partnered readouts.
Verification
Confirm timing and program details against the company announcement or filing.